BiVictriX Therapeutics


BiVictriX was founded in 2017 to exploit a unique and highly novel approach that delivers a step-change in the target selectivity of cancer biotherapeutics. Through targeting cancer-restricted cell surface antigen fingerprints, BiVictriX delivers a pipeline of highly differentiated bispecific therapeutics that have improved potency together with substantially wider therapeutic indices.